Indiana Biosciences Research Institute Inc. and Indiana University have jointly identified tyrosine-protein kinase Lyn inhibitors described as potentially useful for the treatment of Alzheimer’s disease.
Patients with Parkinson’s disease (PD) frequently suffer from sleep disorders, in addition to the neurodegenerative processes associated with the disease. These disorders affect both rapid eye movement (REM) and non-REM (NREM) sleep, but the underlying mechanisms in PD patients remain largely unknown.
Almirall SA has submitted a CTA filing for a bispecific antibody targeting IL-13 and OX-40L for the treatment of atopic dermatitis. The company expects to initiate a first-in-human phase I trial during the first half of this year.
Hubei Polytechnic University (Huangshi, China) scientists and collaborators aimed to develop potential tubulin polymerization inhibitors that may also synergize with immunotherapies for cancer treatment.
Nextpoint Therapeutics Inc. has obtained IND clearance from the FDA to initiate clinical development of NPX-372, a first-in-class B7-H7-targeted T-cell engager (TCE) for the treatment of patients with solid tumors.
Zhejiang Difference Biological Technology Co. Ltd. (Diff Biotech)’s proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, has received clinical trial approval from China’s National Medical Products Administration (NMPA).
Researchers from the Medical University of South Carolina report the development of novel genetic mouse models that enable pericyte chemogenetic modulation, which could reduce neuronal damage and cognitive decline in Alzheimer’s disease.
Hepatocellular carcinoma (HCC) is the most common form of primary liver cancer, representing approximately 75-85% of all cases. Often considered preventable, primary liver cancer ranks as the sixth most frequently diagnosed cancer and the third leading cause of cancer deaths worldwide. Through a multi-institutional effort, researchers have identified activated ATF6α as a driver of HCC that suppresses immune defenses, predicts response to immune checkpoint therapy, and represents a potential target for intervention.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have discovered heterocyclic carbonyl derivatives acting as muscarinic M4 receptor agonists potentially useful for the treatment of pain, substance abuse and dependency, schizophrenia, Alzheimer’s disease and sleep disorders.
Scientists from the Korea Research Institute of Chemical Technology and Yonsei University have identified N4-(indolin-7-yl)-N2-(2-alkoxypyridin-3-yl)pyrimidine-2,4-diamine derivatives acting as EGFR (HER1; erbB1) and/or HER2 (erbB2) mutant inhibitors and therefore reported to be useful for the treatment of cancer.
RSS
